Status:
COMPLETED
Aflibercept (Eylea) in roUtine Clinical Practice in patientS With Wet Age-related Macular Degeneration in Italy
Lead Sponsor:
Bayer
Conditions:
Wet Macular Degeneration
Eligibility:
All Genders
Brief Summary
The main objectives of this non-interventional cohort field study are to evaluate effectiveness of Eylea and to describe follow-up as well as treatment patterns in patients with wAMD (wet age-related ...
Eligibility Criteria
Inclusion
- "Naïve" patients with wet AMD(age-related macular degeneration) treated with Eylea (in accordance with the local Summary of Product Characteristics, SPC).
Exclusion
- Exclusion criteria as listed in the local SPC. Scar, fibrosis, or atrophy involving the center of the fovea in the study eye.
- Any concomitant therapy with another agent to treat wet AMD in the study eye.
- Any prior or concomitant therapy with another drug for wAMD.
Key Trial Info
Start Date :
January 9 2015
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 8 2019
Estimated Enrollment :
912 Patients enrolled
Trial Details
Trial ID
NCT02289924
Start Date
January 9 2015
End Date
July 8 2019
Last Update
November 7 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Multiple Locations, Italy